biphasic human insulin 30 · Diabetes Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
biphasic human insulin 50 · Diabetes Biphasic human insulin 50 is a combination insulin product that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
biphasic insulin aspart · Diabetes Biphasic insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, with a biphasic formulation providing both immediate and intermediate insulin coverage.
biphasic insulin aspart 30 · Diabetes Biphasic insulin aspart 30 is a premixed insulin that combines rapid-acting insulin aspart with intermediate-acting insulin to provide both immediate and sustained blood glucose control.
biphasic insulin aspart 50 · Diabetes Biphasic insulin aspart 50 is a premixed insulin formulation that provides rapid-acting insulin aspart combined with intermediate-acting insulin to control blood glucose in diabetes.
Eptacog alfa (NovoSeven) · Hematology Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis.
Fiasp® · Diabetes Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.
human insulin · Diabetes Human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
human soluble insulin · Diabetes Human soluble insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
IGlar U100 · Diabetes IGlar U100 is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.
Insulin aspart (NovoRapid®) · Diabetes Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.
Insulin glargine U100 · Diabetes Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.
Insulin-Levemir · Diabetes Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
insulin NPH · Diabetes Insulin NPH is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
isophane human insulin · Diabetes Isophane human insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
NPH insulin · Diabetes NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Placebo semaglutide Placebo semaglutide is an inactive formulation containing no active pharmaceutical ingredient and produces no pharmacological effect.
soluble human insulin · Diabetes Soluble human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Phase 3 pipeline
biphasic insulin aspart 70 · Diabetes Biphasic insulin aspart 70 works by mimicking the body's natural insulin production to regulate blood sugar levels.
CagriSema · Endocrinology / Diabetes CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.
Etavopivat A · Hematology/Oncology Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase fetal hemoglobin (HbF) production and reduce hemolysis in patients with sickle cell disease.
Etavopivat B · Hematology/Rare Blood Disorders Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.
Etavopivat C · Hematology/Rare Blood Disorders Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.
Faster-acting insulin aspart · Diabetes Faster-acting insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Faster aspart · Diabetes Faster aspart is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.
IcoSema · Endocrinology IcoSema is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
Insulin Glargine 100U/mL · Diabetes Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.
NNC0365-3769 (Mim8) · Diabetes Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist.
NNC0365-3769 (Mim8) PPX · Diabetes Mim8 PPX is a glucagon-like peptide-1 (GLP-1) receptor agonist.
NNC0487-0111 · Diabetes, Obesity NNC0487-0111 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
NNC6019-0001 · Diabetes NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control.
oral anti-diabetic drug · Diabetes Works by stimulating the release of insulin from the pancreas.
Placebo cagrilintide · Obesity / Metabolic disease Cagrilintide is an amylin receptor agonist that slows gastric emptying and promotes satiety to reduce appetite and food intake.
Placebo (canagliflozin) · Diabetes Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.
Placebo I (Semaglutide) · Diabetes, Obesity, Cardiovascular Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Placebo II (Semaglutide) · Diabetes, Obesity Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Placebo insulin icodec · Diabetes Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.
Placebo (Mim8) Placebo (Mim8) is an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.
Placebo (ziltivekimab) · Cardiovascular Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation.
repaglinide and metformin combination tablet · Diabetes Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.
rosiglitazone and metformin combination tablet · Diabetes Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Semaglutide B · Diabetes Semaglutide B is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.
Semaglutide J · Diabetes, Obesity Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying.
Turoctocog alfa pegol (N8-GP) · Hematology Turoctocog alfa pegol is a recombinant human coagulation factor VIII with extended half-life achieved through PEGylation, which replaces deficient clotting factor in hemophilia A patients.
Ziltivekimab B · Autoimmune diseases Ziltivekimab B is an interleukin-1 beta (IL-1β) inhibitor.
Ziltivekimab C · Cardiovascular Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk.